A5031977714- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- Biosimilars and Bioanalytical Methods
- Ubiquitin and proteasome pathways
- T-cell and Retrovirus Studies
- Viral Infectious Diseases and Gene Expression in Insects
- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- Epigenetics and DNA Methylation
- Hematopoietic Stem Cell Transplantation
- Glycosylation and Glycoproteins Research
Centre Hospitalier Universitaire de Montpellier
2016-2025
Université de Montpellier
2016-2025
Centre National de la Recherche Scientifique
2016-2025
Hôpital Saint Eloi
2012-2024
Centre Hospitalier Universitaire de Tours
2003-2023
Institut de Génétique Moléculaire de Montpellier
2020-2023
Inserm
2007-2023
Hôpital 20 Août
2023
Institut Universitaire de Recherche Clinique
2016-2023
Clinique du Millénaire
2015-2023
Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and central to the survival of chronic lymphocytic leukemia cells. We evaluated efficacy venetoclax in combination with rituximab patients relapsed or refractory leukemia.In this randomized, open-label, phase 3 trial, we randomly assigned 389 receive for up 2 years (from day 1 cycle 1) plus first 6 months (venetoclax-rituximab group) bendamustine (bendamustine-rituximab group). The trial design did not...
Abstract The FCGR3A gene dimorphism generates two allotypes: FcγRIIIa-158V and FcγRIIIa-158F. genotype homozygous for (VV) is associated with higher clinical response to rituximab, a chimeric anti-CD20 IgG1 used in the treatment of B lymphoproliferative malignancies. Our objective was determine whether this genetic association relates rituximab-dependent cytotoxicity mediated by FcγRIIIa/CD16a+ cells. number CD16+ circulating monocytes, T cells, natural killer (NK) cells 54 donors first...
The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab a bispecific antibody that recruits T cells to tumor cells.In the phase 2 part of 1-2 study, we enrolled DLBCL who had received at least two lines therapy previously. Patients pretreatment obinutuzumab mitigate cytokine release syndrome, followed by fixed-duration glofitamab monotherapy (12 cycles total). primary end point was complete response according assessment an independent...
Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose 375 mg per square meter body-surface area administered every 2 months for 3 years transplantation would prolong the duration response.
Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most will have a relapse. Combination immunotherapy lenalidomide and rituximab is an immunomodulatory regimen that promising activity indolent B-cell non-Hodgkin's lymphoma.
Abstract Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel tisa-cel were registered retrospective French DESCAR-T registry study ( NCT04328298 ). After 1:1 propensity...
In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine (BR) patients relapsed or refractory chronic lymphocytic leukemia (CLL). At 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and predictive value molecular genetic characteristics.Patients CLL were randomly assigned 2 years (VenR for first six cycles) cycles BR. PFS, overall (OS),...
Abstract Prolonged Covid‐19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in‐hospital stay (LOS) due among and assess its determinants outcomes. Adult admitted 16 French hospitals in March April, 2020 were included. Length was analyzed as a competitor vs death. The study included 111 patients. median age 65 years (range, 19–92). Ninety‐four (85%) had B‐cell non‐Hodgkin lymphoma. Within the 12 months prior hospitalization...
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine in Participants Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) relapsed/refractory (R/R) CLL. Patients were randomized 2 years VenR (n = 194; rituximab for first 6 months) months BR 195). Although...
Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, significant number patients experience failure. Among 550 registered French registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with median follow-up 7.9 months. At registration, 57.0% presented an age-adjusted International Prognostic Index 2 to 3, 18.9% had Eastern Cooperative Oncology Group performance status ≥2, 57.1%...
Abstract Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem transplantation (ASCT); however, clinical practice, roughly half R/R LBCL are deemed unsuitable candidates ASCT. The axi-cel remains be ascertained transplant-ineligible patients. ALYCANTE, an open-label, phase 2 study, evaluated a 62 who were...
An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and high-risk disease features, such as progression of within 24 months (POD24) from first-line immunochemotherapy or refractory to both CD20-targeting agent alkylator (double refractory), due no established standard care poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two more lines prior systemic therapy, but there consensus on its optimal timing the course...
Obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell (MCL) xenograft models. In phase I of our study, obinutuzumab (GA101) exhibited encouraging activity but no clear dose-response relationship, few patients had aggressive histologies. The efficacy safety two doses were explored randomized II trial with heavily pretreated DBLCL MCL.Patients randomly assigned receive...
To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas.Patients with histologically confirmed peripheral lymphoma (PTCL) cutaneous who progressed after one more lines prior chemotherapy received at 120 mg/m(2) per day on days 1 through 2 every 3 weeks for six cycles. The primary end point was overall response rate (ORR). Secondary points were duration (DOR), progression-free survival (PFS), (OS).Of 60 patients included, 27 (45%) to...
The phase II part of the I/II GAUGUIN study evaluated efficacy and safety two different doses obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, in patients with relapsed/refractory indolent non-Hodgkin lymphoma.Patients were randomly assigned to receive eight cycles (GA101) as flat dose 400 mg on days 1 8 cycle also day 2 (400/400 mg) or 1,600 800 (1,600/800 mg).Forty enrolled, including 34 follicular lymphoma; 38 40 had previously received rituximab...